6533b81ffe1ef96bd12786ca

RESEARCH PRODUCT

Synergistic Antioncogenic Activity of Azacitidine and Curcumin in Myeloid Leukemia Cell Lines and Patient Samples.

Marisa CalabuigIván MartínPaula AmatM J RemigiaJuan Carlos Hernández-boludaCarlos SolanoEva VillamónMar TormoFrancisca GarcíaBlanca Navarro

subject

MaleCancer ResearchMyeloidCurcuminAzacitidineAntineoplastic AgentsApoptosis03 medical and health scienceschemistry.chemical_compound0302 clinical medicineCell Line TumormedicineHumansAgedAged 80 and overbusiness.industryCell CycleMyeloid leukemiaCell DifferentiationDrug SynergismGeneral MedicineCell cyclemedicine.anatomical_structureOncologychemistryHypomethylating agentApoptosisLeukemia Myeloid030220 oncology & carcinogenesisMyelodysplastic SyndromesCancer researchCurcuminAzacitidineFemaleBone marrowbusinessmedicine.drug

description

Background/aim Azacitidine (AZA) is a hypomethylating agent used in myeloid neoplasms, however, approximately half of patients show treatment failure or relapse. This in vitro study investigated the effect of the combination of AZA with the natural compound curcumin (CUR) in increasing its efficacy. Materials and methods We analyzed the effects of AZA plus CUR on proliferation, apoptosis, cell cycle and differentiation in myeloid leukemic cell lines (U-937, HL-60, K-562, and OCI-AML3) and bone marrow samples of patients. Results The results showed a synergy between AZA and CUR in all leukemic lines and in most leukemic samples, with a decrease in proliferation and an increase in apoptosis compared to the activity of each drug separately. In addition, AZA plus CUR showed low cytotoxicity in healthy samples. Conclusion A remarkable antioncogenic effect of the combination of AZA plus CUR was shown, providing a basis for future studies analyzing the clinical efficacy of these drugs.

yearjournalcountryeditionlanguage
2019-07-18Anticancer research
10.21873/anticanres.13659https://pubmed.ncbi.nlm.nih.gov/31519576